OncoMatch/Clinical Trials/NCT06055816

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Is NCT06055816 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Endostar and Envafolimab for nasopharyngeal carcinoma.

Phase 2RecruitingZhejiang Cancer HospitalNCT06055816Data as of May 2026

Treatment: Endostar and Envafolimab — Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVA

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiotherapy

Prior radiotherapy

Cannot have received: cytotoxic chemotherapy

cytotoxic chemotherapy

Cannot have received: immunotherapy

immunotherapy

Cannot have received: target therapy

target therapy

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify